<DOC>
	<DOCNO>NCT02526290</DOCNO>
	<brief_summary>In study , safety effectiveness Oculeve Intranasal Lacrimal Neurostimulator 180 day use participant aqueous tear deficiency evaluate .</brief_summary>
	<brief_title>Six Month Study Evaluate Safety Effectiveness Intranasal Lacrimal Neurostimulator</brief_title>
	<detailed_description>This prospective , single-arm , multicenter , open-label clinical trial participant use Oculeve Intranasal Lacrimal Neurostimulator stimulate tear production 180 day . Participants Screening Visit within 60 day prior initial device application . Device application initiate Day 0 , time participant receive train proper use device . Participants receive follow-up visit Days 7 , 30 , 90 180 .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<criteria>Subjects moderate severe dry eye disease Literate , able speak English Spanish , able complete questionnaire independently Willing sign inform consent deem capable complying requirement study protocol Chronic recurrent epistaxis , coagulation disorder condition , opinion investigator , may lead clinically significant increase bleed Nasal sinus surgery ( include history application nasal cautery ) significant trauma Cardiac demand pacemaker , implanted defibrillator implant electronic device Diagnosis epilepsy Corneal transplant either eyes Participation clinical trial new active substance new device within 30 day Screening Visit Women pregnant , planning pregnancy , nurse Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>